XML 185 R31.htm IDEA: XBRL DOCUMENT v3.24.0.1
Collaboration and license agreements (Tables)
 12 Months Ended
Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Allocation of total transaction price and unsatisfied transaction price
The following table summarizes the allocation of the total transaction price to the identified performance obligations under the arrangement, and the amount of the transaction price unsatisfied as of December 31, 2023 (in thousands):
Transaction
Price
Allocated
Transaction
Price
Unsatisfied
Performance obligations:
Research and development targets$61,149 $17,394 
Option rights6,757 1,670 
Total$67,906 $19,064 
Schedule of revenue from collaboration agreements
Revenue from collaboration agreements was as follows (in thousands):
Years Ended December 31,
20232022
Revenue from collaboration agreements:
Roche Agreement$9,063 $4,939 
Biogen Agreement10,623 19,214 
Calico Agreement1,070 6,943 
Betta Agreement— — 
Total revenue from collaboration agreements$20,756 $31,096 
Schedule of financial information related to collaboration and license agreements
Supplemental information related to the collaboration and license agreements consisted of the following in the Company’s consolidated balance sheet as of December 31, 2023 (in thousands):
Accounts
Receivable
Deferred
Revenue,
Current
Deferred
Revenue,
Net of Current
Deferred
Revenue,
Total
Supplemental information:
Roche Agreement$— $2,667 $11,814 $14,481 
Betta Agreement1,799 4,000 8,000 12,000 
Merck Agreement10,000 8,000 2,000 10,000 
Biogen Agreement— 804 — 804 
Total$11,799 $15,471 $21,814 $37,285 
Supplemental information related to the collaboration and license agreements consisted of the following in the Company’s consolidated balance sheet as of December 31, 2022 (in thousands):
Accounts
Receivable
Deferred
Revenue,
Current
Deferred
Revenue,
Net of Current
Deferred
Revenue,
Total
Supplemental information:
Roche Agreement$417 $4,649 $16,895 $21,544 
Biogen Agreement— 11,427 — 11,427 
Calico Agreement1,056 542 — 542 
Total$1,473 $16,618 $16,895 $33,513 
Schedule of supplemental financial information related to collaboration and license agreements
Supplemental financial information related to the collaboration and license agreements are (in thousands):
Years Ended December 31,
20232022
Revenue recognized that was included in the contract liability at the beginning of the period$20,185 $25,412 
Revenue recognized from performance obligations fully or partially satisfied in previous periods43 518